Dennis Hallahan

Professor of Radiation Oncology, Elizabeth H and James S McDonnell III Distinguished Professor of Medicine, Head of the Department of Radiation Oncology, Professor of Cell Biology and Physiology, Professor of Pathology and Immunology, Professor of Molecular Microbiology, Professor of Biomedical Engineering

    • 12305 Citations
    1986 …2020

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    Dennis Hallahan, MD has 20+ years of uninterrupted NCI/NIH funding. The Hallahan laboratory has discovered several molecular targets for drug development in cancer. Discovery strategies have included Proteomics and lipidomics. These discoveries have gone on to preclinical and clinical drug development of a number of novel cancer drugs. Most notable are inhibitors of PLA2 and the LPA receptor. More recently, the Hallahan laboratory has identified TIP1 and GRP78 as molecular targets to enhance the efficacy of radiation therapy. Dr. Hallahan’s lab has developed monoclonal antibodies and scFv antibodies to radiation inducible neoantigens that are specific to cancer. These antibodies activate immune effector cells. They have also been conjugated to therapeutic agents such as radiopharmaceuticals. More importantly, antibodies to radiation inducible TIP1 and GRP78 show efficacy in mouse models of human cancer. The Hallahan laboratory has developed several drug delivery systems using nanoparticles and liposomes. These particles have been conjugated to peptide ligands that bind to radiation inducible receptors in cancer. This approach has increased the bioavailability of doxorubicin and paclitaxel specifically to cancer. Pre-clinical efficacy and proof of concept studies have been completed. Current research combines our lead cancer specific ligand conjugated to PEG in liposomal formulation.

    Areas of Clinical Interest

    Brain tumors, cancer of the central nervous system, cancer antibody development, immunotherapy, cancer drug development, radiation protecting drugs, nanoparticles, cancer drug delivery gene therapy for cancer

    Fingerprint Dive into the research topics where Dennis Hallahan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 29 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output

    Characterization of magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-induced large-volume hyperthermia in deep and superficial targets in a porcine model

    Zhu, L., Lam, D., Pacia, C. P., Gach, H., Partanen, A., Talcott, M. R., Greco, S. C., Zoberi, I., Hallahan, D. E., Chen, H. & Altman, M., Jan 1 2020, In : International Journal of Hyperthermia. 37, 1, p. 1159-1173 15 p.

    Research output: Contribution to journalArticle

    Open Access
  • Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow

    Kapoor, V., Collins, A., Griffith, K., Ghosh, S., Wong, N., Wang, X., Challen, G. A., Krambs, J., Link, D., Hallahan, D. E. & Thotala, D., May 12 2020, In : Oncotarget. 11, 19, p. 1681-1690 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • TAF15 contributes to the radiation-inducible stress response in cancer

    Singh, A. K., Kapoor, V., Thotala, D. & Hallahan, D. E., Jul 1 2020, In : Oncotarget. 11, 27, p. 2647-2659 13 p.

    Research output: Contribution to journalArticle

    Open Access